PHILADELPHIA, May 03, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) today announced that members of its management team will participate in three upcoming conferences in May:
- Deutsche Bank 41st Annual Healthcare Conference on Wednesday, May 4, 2016, at 8:00 a.m. at The InterContinental, Boston
- Piper Jaffray GenomeRX Symposium on Tuesday, May 17, 2016, at The InterContinental, New York City
- UBS 2016 Global Healthcare Conference May 23-25, 2016, at the Grand Hyatt, New York City.
About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com
Contacts Investor Relations Spark Therapeutics, Inc. Stephen W. Webster Chief Financial Officer (855) SPARKTX (1-855-772-7589) Media Ten Bridge Communications Dan Quinn (781) 475-7974 firstname.lastname@example.org
Source:Spark Therapeutics, Inc.